Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
about
Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.Involvement of soluble B7-H3 in combination with the serum inflammatory cytokines interleukin-17, -8 and -6 in the diagnosis of hepatocellular carcinoma.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.
P2860
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Clinical Validity and Utility ...... Current and Future Directions.
@en
type
label
Clinical Validity and Utility ...... Current and Future Directions.
@en
prefLabel
Clinical Validity and Utility ...... Current and Future Directions.
@en
P2093
P2860
P356
P1476
Clinical Validity and Utility ...... Current and Future Directions.
@en
P2093
Balaji Virassamy
Lironne Wein
Peter Savas
Roberto Salgado
Stephen J Luen
P2860
P356
10.3389/FONC.2017.00156
P50
P577
2017-08-03T00:00:00Z